ABBVIE INC. ABBV
$215.70
+0.56%
at last close
Key Stats
- Today's Range
- $215.70 – $220.01
- 50-Day Range
- $190.75 – $228.62
- 52-Week Range
- $168.54 – $244.81
- Volume
- 5.41 million shs
- Average Volume
- 6.45 million shs
- Market Cap
- $381.10 billion
- P/E Ratio
- 106.26
- Dividend Yield
- 3.21%
Valuation
- P/E Ratio
- 106.26
- Price / Book
- -57.64
- Price / Sales
- 6.07
Dividend
- Dividend Yield
- 3.21%
- Annual Dividend
- $6.92
- Payout Ratio
- 340.89%
- Ex-Dividend Date
- 2026-04-15
Short Interest
- Short Interest
- 0.85%
- Days to Cover
- 5.34
Financials (TTM)
- Revenue
- $62.82 billion
- Net Income
- $3.64 billion
- Net Margin
- 5.80%
- Return on Equity
- -55.08%
- Debt-to-Equity
- —
About ABBVIE INC.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.